产品
编 号：F285121
分子式：C3H7O4P
分子量：138.06
分子式：C3H7O4P
分子量：138.06
产品类型
规格
价格
是否有货
结构图
CAS No: 23155-02-4
产品详情
生物活性：
Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
体内研究：
Fosfomycin (80 mg/kg; i.v. or p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats.Pharmacokinetic of Fosfomycin in RatsDibekacin Dose (mg)Vdss (l/kg)β (min-1)T1/2 (min)Urinary recovery (%)
300.2610.024428.485
Animal Model:Fischer 344 rats
Dosage:320 mg/kg
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)
Dosage:120 mg/kg
Administration:Intravenous injection; once
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters. Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria.
体内研究：
Fosfomycin (80 mg/kg; i.v. or p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats.Pharmacokinetic of Fosfomycin in RatsDibekacin Dose (mg)Vdss (l/kg)β (min-1)T1/2 (min)Urinary recovery (%)
300.2610.024428.485
Animal Model:Fischer 344 rats
Dosage:320 mg/kg
Administration:Intramuscular injection, 5 schedules: 1 h, 0.5 h earlier than dibekacin, concomitantly, 0.5 h later and 1 h later; 11 days
Result:Reduced polyuria, proteinuria, enzymes and cytosine caused by dibecacin (40 mg/kg), followed by the previous treatment.
Animal Model:Dehydrated Wistar rat with acute renal failure (8-week-old)
Dosage:120 mg/kg
Administration:Intravenous injection; once
Result:Recovered the exclusion rate of rats basically to normal, and improved the nephrotoxicity parameters. Protects proximal tubular lysosomes from aminoglycosides by inhibiting myeloid formation and protecting the integrity of lysosomal membrane of rats treated with double bekacin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备